Close

Anti-CD171 (CE7) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX326)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CD171 (CE7) h(28OXζ), which is constructed for the engineering of T cells to target human CD171. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CD171 antibody linked to a CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of Neuroblastoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD171
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Neuroblastoma
  • Generation
  • Third
  • Vector Name
  • pSBCAR1
  • Vector Length
  • ~6kb
  • Vector Type
  • Sleeping Beauty (SB) transposon
  • Receptor Construction
  • scFv-CD28-OX40-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    OX40
    OX40, also known as CD134 or TNFRSF4 is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation. The interaction between OX40 and its binding partner, OX40L (CD252) plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells and modulate cytokine receptor signaling. OX40 cosignaling in CAR improve redirected T-cell effector functions and enhance anti-tumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • CE7
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • L1CAM
  • Synonyms
  • L1CAM

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 Cell-surface expression of L1-CAM in various ovarian tumor lines including CAOV-3, OVCAR-3, SK-OV-3, MADH2744, and A2780 were examined by flow cytometry via clone CE7.

CAR Construction : Latest CAR Construction

Fig.1 Cell-surface expression of L1-CAM in various ovarian tumor lines including CAOV-3, OVCAR-3, SK-OV-3, MADH2744, and A2780 were examined by flow cytometry via clone CE7.

Mean fluorescent intensity (MFI) and percentages of cells with positive staining (%, red histograms) over secondary reagent alone (black histograms) are indicated.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

CAR scfv data FCM

Fig.2 Flow cytometric analysis of surface expressed Fc-containing CE7-CAR, CD19t, CD4, or CD8 (grey histogram) compared to staining with either isotype controls or SA-PE alone (open histograms).

CAR Construction : Latest CAR Construction

Fig.2 Flow cytometric analysis of surface expressed Fc-containing CE7-CAR, CD19t, CD4, or CD8 (grey histogram) compared to staining with either isotype controls or SA-PE alone (open histograms).

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.3 Cytolytic activity of CE7R+ TCM cells against the indicated ovarian cancer cell line targets was determined by 4-hr 51Cr-release assay.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.3 Cytolytic activity of CE7R+ TCM cells against the indicated ovarian cancer cell line targets was determined by 4-hr 51Cr-release assay.

LCL-OKT3 was used as positive control target. Mean % chromium release ± S.D. of triplicate wells are depicted.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.4 IFN-γ and TNF-α release quantification of CE7 CAR-Ts co-cultured with the indicated tumor lines.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.4 IFN-γ and TNF-α release quantification of CE7 CAR-Ts co-cultured with the indicated tumor lines.

CE7-CAR+ TCM cells were co-cultured with the indicated tumor lines at a 10:1 ratio for 21 hrs and supernatants were analyzed for IFN-γ and TNF-α levels by cytometric bead array. Means + S.E.M. of triplicate wells are depicted.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FCM

Fig.5 Flow cytometric analysis of CE7-CAR TCM cells prior to use in vivo.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.5 Flow cytometric analysis of CE7-CAR TCM cells prior to use in vivo.

Percentages of positive cells in each quadrant are indicated.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.6 CE7-CAR+ TCM Cells Inhibit Intraperitoneal Ovarian Tumor Growth in Vivo.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.6 CE7-CAR+ TCM Cells Inhibit Intraperitoneal Ovarian Tumor Growth in Vivo.

NSG mice received i.p. injection of ffLuc+ SK-OV-3 tumor cells on day 0, and were randomized into 4 groups (n = 6 mice per group) for treatment with CE7-CAR transduced T cells i.p. (i.e, days 5 and 12).

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.7 CE7-CAR+ TCM Cells Inhibit Intraperitoneal Ovarian Tumor Growth in Vivo.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.7 CE7-CAR+ TCM Cells Inhibit Intraperitoneal Ovarian Tumor Growth in Vivo.

Quantitative bioluminescence imaging of for each group over the time. Mean ± S.E. of total flux levels of luciferase activity were measured.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FCM

Fig.8 Flow cytometric detection of T cells in peripheral blood 8 days after the second dose of CE7-CART cells were administered.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.8 Flow cytometric detection of T cells in peripheral blood 8 days after the second dose of CE7-CART cells were administered.

Representative histograms and percentages of human CD45+ cells (mean + S.D.) are depicted for each group of mice.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.9 Kaplan-Meier analysis of survival for CE7-CAR treatment group.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.9 Kaplan-Meier analysis of survival for CE7-CAR treatment group.

p ≤ 0.001 when the CE7-CAR+ T cell treated group was compared to any other group using the Log-rang (Mantel-Cox) test.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.10 Treatment with CE7-CAR+ T Cells Results in Less Ascites Rormation and Reduced L1-CAM Expression on Residual Tumors.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.10 Treatment with CE7-CAR+ T Cells Results in Less Ascites Rormation and Reduced L1-CAM Expression on Residual Tumors.

Representative images of ascites formation in control mice (PBS, mock or CD19R+ T cell treated groups) versus CE7R+ T cell treated mice.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.11 Treatment with CE7-CAR+ T Cells Results in Less Ascites Rormation and Reduced L1-CAM Expression on Residual Tumors.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.11 Treatment with CE7-CAR+ T Cells Results in Less Ascites Rormation and Reduced L1-CAM Expression on Residual Tumors.

Tumor nodules were resected from each mouse upon euthanasia when mice became moribund and subjected to immunohistochemical staining via CE7 monoclonal antibody.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.12 CE7-CAR+ T Cells Specifically Recognized and Killed L1-CAM-Expressing Primary Ovarian Cancer Cells Derived from Malignant Ascites.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.12 CE7-CAR+ T Cells Specifically Recognized and Killed L1-CAM-Expressing Primary Ovarian Cancer Cells Derived from Malignant Ascites.

CE7-CAR+ T cells were co-cultured overnight with the indicated tumor lines at a 10:1 ratio and supernatants were analyzed for IFN-γ and TNF-α levels by cytometric bead array.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

Complete CAR data FuncS

Fig.13 CE7-CAR+ T Cells Specifically Recognized and Killed L1-CAM-Expressing Primary Ovarian Cancer Cells Derived from Malignant Ascites.

CAR Construction : CE7 scfv-CD3ζ Latest CAR Construction

Fig.13 CE7-CAR+ T Cells Specifically Recognized and Killed L1-CAM-Expressing Primary Ovarian Cancer Cells Derived from Malignant Ascites.

CE7-CAR+ T cells against the indicated cancer cell lines targets was determined by 4-hr 51Cr-release assay.

Hong, H., Brown, C. E., Ostberg, J. R., Priceman, S. J., Chang, W. C., Weng, L., ... & Forman, S. J. (2016). L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS One, 11(1), e0146885.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD171 (CE7) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX326). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.